**Question:** Tyrosine kinase inhibitor with HER2/NEU receptor inhibition property?

**Core Concept:**
Tyrosine kinase inhibitors (TKIs) are a class of drugs that target and inhibit the activity of specific enzymes called tyrosine kinases. In this case, we are discussing a TKI that inhibits the Human Epidermal Growth Factor Receptor 2 (HER2/NEU) receptor. HER2/NEU is a protein that is overexpressed or amplified in certain types of cancer, particularly in breast cancer.

**Why the Correct Answer is Right:**
The correct answer is **D.** Trastuzumab (Herceptin) is a monoclonal antibody that specifically binds to the extracellular domain of the HER2/NEU receptor, preventing it from activating downstream signaling pathways that promote cancer cell growth, division, and survival. By doing so, trastuzumab helps to slow down or halt the progression of HER2-overexpressing cancers.

**Why Each Wrong Option is Incorrect:**
A. Option A is incorrect because it refers to gefitinib (Iressa), which is a TKI that targets the epidermal growth factor receptor (EGFR) family, particularly EGFR, rather than HER2/NEU.

B. Option B is incorrect because it mentions lapatinib (Tykerb), another TKI, but lapatinib targets both EGFR and HER2/NEU, not just HER2/NEU as required by the question.

C. Option C is incorrect because pertuzumab (Perjeta) is a monoclonal antibody that targets the extracellular domain of HER2/NEU, not a TKI that inhibits the receptor directly.

**Clinical Pearl:**
HER2/NEU overexpression can serve as a useful biomarker in cancer diagnosis and treatment planning. HER2/NEU overexpression indicates a poor prognosis and aggressive disease course in breast cancer. In such cases, trastuzumab is often used in combination with other chemotherapy drugs to improve treatment outcomes.

**Correct Answer:** D. Trastuzumab (Herceptin) is a monoclonal antibody that specifically targets the HER2/NEU receptor, inhibiting its activation and preventing cancer cell growth and division. This is a key example of personalized medicine, as trastuzumab is used specifically for HER2/NEU-positive breast cancers.